Combination tablets of lumacaftor and ivacaftor formulated for cystic fibrosis therapy in patients with specific CFTR mutations. Pharmaceutical manufacturers supply to wholesalers, hospitals, and specialty pharmacies for distribution in healthcare networks serving respiratory care facilities.